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Pharmacological Modulation of Photoreceptor Outer Segment
Degradation in a Human iPS Cell Model of Inherited Macular
Degeneration
Abstract
Degradation of photoreceptor outer segments (POS) by retinal pigment epithelium (RPE) is essential for
vision, and studies have implicated altered POS processing in the pathogenesis of some retinal degenerative
diseases. Consistent with this concept, a recently established hiPSC-RPE model of inherited macular
degeneration, Best disease (BD), displayed reduced rates of POS breakdown. Herein we utilized this model to
determine (i) if disturbances in protein degradation pathways are associated with delayed POS digestion and
(ii) whether such defect(s) can be pharmacologically targeted. We found that BD hiPSC-RPE cultures
possessed increased protein oxidation, decreased free-ubiquitin levels, and altered rates of exosome secretion,
consistent with altered POS processing. Application of valproic acid (VPA) with or without rapamycin
increased rates of POS degradation in our model, whereas application of bafilomycin-A1 decreased such rates.
Importantly, the negative effect of bafilomycin-A1 could be fully reversed by VPA. The utility of hiPSC-RPE
for VPA testing was further evident following examination of its efficacy and metabolism in a complementary
canine disease model. Our findings suggest that disturbances in protein degradation pathways contribute to
the POS processing defect observed in BD hiPSC-RPE, which can be manipulated pharmacologically. These
results have therapeutic implications for BD and perhaps other maculopathies.
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Degradation of photoreceptor outer segments (POS) by 
retinal pigment epithelium (RPE) is essential for vision, 
and studies have implicated altered POS processing in 
the pathogenesis of some retinal degenerative diseases. 
Consistent with this concept, a recently established 
hiPSC-RPE model of inherited macular degeneration, 
Best  disease (BD), displayed reduced rates of POS break-
down. Herein we utilized this model to determine (i) if 
disturbances in protein degradation pathways are asso-
ciated with delayed POS digestion and (ii) whether such 
defect(s) can be pharmacologically targeted. We found 
that BD hiPSC-RPE cultures possessed increased protein 
oxidation, decreased free-ubiquitin levels, and altered 
rates of exosome secretion, consistent with altered POS 
processing. Application of valproic acid (VPA) with or 
without rapamycin increased rates of POS degradation 
in our model, whereas application of bafilomycin-A1 
decreased such rates. Importantly, the negative effect of 
bafilomycin-A1 could be fully reversed by VPA. The util-
ity of hiPSC-RPE for VPA testing was further evident fol-
lowing examination of its efficacy and metabolism in a 
complementary canine disease model. Our findings sug-
gest that disturbances in protein degradation pathways 
contribute to the POS processing defect observed in BD 
hiPSC-RPE, which can be manipulated pharmacologi-
cally. These results have therapeutic implications for BD 
and perhaps other maculopathies.
Received 27 April 2015; accepted 23 July 2015; advance online  
publication 1 September 2015. doi:10.1038/mt.2015.141
INTRODUCTION
Macular degenerative diseases (MDDs) are a complex group 
of disorders that comprise a major cause of blindness world-
wide. Dysfunction of retinal pigment epithelium (RPE) cells 
leading to loss of photoreceptors occurs in a number of MDDs, 
including age-related macular degeneration (AMD). In many 
of these MDDs, accumulation of partially digested photorecep-
tor outer segment (POS) products in RPE cells, possibly due to 
disturbances in protein degradation, has been implicated in dis-
ease progression.1–4
POS are taken up by RPE cells as phagosomes, which fuse 
with lysosomes to create phagolysosomes that are capable of 
degrading their cargo.5,6 A recent study has demonstrated a role 
for noncanonical autophagy in the POS degradation process as 
well.7 Coordination of POS degradation, proteolysis, and release 
of cellular waste products by RPE cells requires a collaborative 
effort between the proteasome, lysosome, autophagy, and exo-
cytotic pathways. In corroboration of this concept, alterations in 
the cellular ubiquitin-proteasome system (UPS) and exocytosis 
have been associated with MDD pathophysiology,8–12 and a single 
nucleotide variation in ubiquitin ligase (UBE3D) was recently 
linked to an increased incidence of AMD.12
To date, the role of protein degradation pathways in RPE 
physiology and MDD has largely been deciphered using geneti-
cally engineered mouse models, cultured human fetal RPE, 
and transformed RPE cell lines (ARPE19) exposed to oxidative 
stressors.9,11,13–15 Human induced pluripotent stem cells (hiPSCs) 
offer a particularly attractive platform to interrogate disease 
pathophysiology using a patient’s own cells, thus increasing the 
likelihood that they recapitulate important disease mechanisms. 
hiPSC-derived disease model systems also permit manipulation 
of cellular environment, and thus are conducive to drug testing. 
Importantly for such studies, we and others have shown that 
hPSC-RPE demonstrates key physical and functional attributes of 
mature RPE in vivo.16–25
We recently developed a patient-derived hiPSC-RPE model of 
Best disease (BD), a slowly progressive, untreatable form of MDD 
with autosomal dominant inheritance. BD hiPSC-RPE displayed 
delayed RHODOPSIN (RHO) degradation and increased accu-
mulation of autofluorescent material after POS feeding.2 As such, 
this BD hiPSC-RPE model offers a unique opportunity to investi-
gate protein degradation pathways and search for drugs that affect 
the rate of POS degradation in patient-derived RPE.
In the current study, we show that in addition to POS handling 
defects, BD hiPSC-RPE displays increased baseline levels of oxi-
dized proteins, decreased free-ubiquitin levels, and an elevated rate 
of exocytosis, suggesting that perturbations in protein degradation 
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pathways contribute to disease pathophysiology. Furthermore, we 
demonstrate that the BD phenotype can be partially mimicked in 
control hiPSC-RPE by treatment with BafA1, a V-ATPase inhibi-
tor that inhibits autophagy and lysosomal function.26,27 Conversely, 
the US Food and Drug Administration (FDA)–approved HDAC 
inhibitor valproic acid (VPA) increased the kinetics of POS break-
down in both control and BD hiPSC-RPE. Combinatorial drug 
therapy consisting of VPA and the autophagy inducer rapamycin 
(RAPA)28 was even more effective in increasing the rate of POS 
degradation in BD hiPSC-RPE. Early treatment of a canine model 
of autosomal recessive BD with VPA yielded promising results; 
however, serum studies revealed that dogs rapidly metabolize 
VPA, limiting their utility for testing this drug. These findings have 
therapeutic implications for the treatment of BD and other macu-
lopathies where defective POS handling instigates or exacerbates 
MDD progression. In addition, our study presents a scenario in 
which a hiPSC model system may be a useful option for testing 
drug efficacy when available animal models are suboptimal.
RESULTS
Accumulation of POS-derived autofluorescent 
material and increased baseline carbonylated protein 
content in BD hiPSC-RPE
Two hiPSC lines were derived from each of two BD patients with 
missense mutations in BEST1 (BD-1: A146K; BD-2: N296H) and 
their unaffected sibling controls (Ctr-1: sibling of BD-1; Ctr-2: sib-
ling of BD-2).2 RPE differentiated from these hiPSC lines displayed 
reproducible, characteristic cobblestone morphology and pigmen-
tation (Figure 1a). Furthermore, when challenged with chronic 
daily POS feeding (1.5 months) followed by 15 days of consecutive 
washes without POS exposure, BD hiPSC-RPE showed increased 
accumulation of autofluorescent material compared to hiPSC-RPE 
derived from sibling controls (representative images from Ctr-1 
and BD-1, Figure 1b, representative images from Ctr-2 and BD-2, 
Supplementary Figure S1A), confirming previous findings.2 No 
autofluorescence was observed in control or BD hiPSC-RPE in 
the absence of POS feeding (data not shown). Given that cellular 
health, oxidative stress, and impaired proteolytic degradation have 
been linked to the accumulation of autofluorescent waste material 
in postmitotic cells,13,14,29,30 we next investigated the levels of carbon-
ylated proteins and oxidative stress modulators in control versus 
BD hiPSC-RPE cells. In the absence of POS feeding, the amount 
of oxidized proteins in BD hiPSC-RPE was higher relative to con-
trol hiPSC-RPE (BD-1 versus Ctr-1: 3.16 ± 0.90-fold, P = 0.055; 
BD-2 versus Ctr-2: 4.56 ± 1.19-fold, P < 0.05; Figure 1c). However, 
there were no clear differences in the relative expression of oxida-
tive stress genes between control and BD hiPSC-RPE (Figure 1d; 
Supplementary Table S1). The finding of increased oxidized protein 
levels in the absence of overt free radical stress implicates impaired 
protein degradation as a possible component of the baseline cellular 
pathophysiology in BD hiPSC-RPE, as well as a contributor to the 
altered POS degradation kinetics seen in this model.2
Altered POS protein degradation, proteasomal 
function, and exocytosis in BD hiPSC-RPE
In experiments aimed at identifying pathways involved in the 
POS handling defect in BD hiPSC-RPE, control and mutant 
hiPSC-RPE were fed unlabeled POS (~20 POS/RPE cell) for 2 
hours, and the amount of intracellular RHO, the most abundant 
protein component of POS, was quantified at 0, 4, 24, 48, and 120 
hours postfeeding (representative images from Ctr-2 and BD-2, 
Figure 2a).16 BD hiPSC-RPE always showed delayed degradation 
of ingested POS compared to control hiPSC-RPE, with RHO pro-
tein present in BD hiPSC-RPE at the 24, 48, and 120 hour time 
points (Figure 2a). Delayed degradation of RHO in BD hiPSC-
RPE was further pronounced when control and mutant hiPSC-
RPE were fed ~50 POS/RPE cell (Supplementary Figure S1B).16  
Similar to our previously published study, no consistent difference 
in the uptake of POS was seen between BD hiPSC-RPE and con-
trol hiPSC-RPE,16 although we occasionally observed less RHO at 
0 hour in the BD group.
Given that BD hiPSC-RPE showed delayed degradation of 
POS, we next investigated whether general intracellular protein 
turnover was affected in BD hiPSC-RPE. We focused first on the 
proteasomal pathway since it plays an essential role in the removal 
of misfolded and oxidized proteins,31–33 and levels of the latter were 
elevated in BD hiPSC-RPE (Figure 1c). Proteasomal activity, mea-
sured by a chymotrypsin-like cell-based assay, was similar in BD 
versus control hiPSC-RPE (BD-1 versus Ctr-1: 1.34 ± 0.43-fold; 
BD-2 versus Ctr-2: 1.11 ± 0.21-fold; Supplementary Figure S2A). 
Furthermore, immunocytochemical analysis did not reveal any 
difference in the localization and expression of ubiquitin (UB) 
between control and BD hiPSC-RPE (Figure 2b). However, the 
protein level of free-UB was lower in BD-2 versus Ctr-2 hiPSC-
RPE (0.68 ± 0.12-fold, P = 0.04; Figure 2c,d and Supplementary 
Figure S2B). Decreased levels of free-UB were also consistently 
observed between BD-1 and Ctr-1 hiPSC-RPE, but this difference 
did not reach statistical significance when averaged across mul-
tiple experiments (Figure 2c and Supplementary Figure S2B,C). 
In contrast, no difference in the amount of poly-UB proteins was 
seen between BD and control hiPSC-RPE (BD-1 versus Ctr-1: 
1.05 ± 0.05-fold; BD-2 versus Ctr-2: 1.06 ± 0.03-fold; Figure 2d 
and Supplementary Figure S2C).
Exocytosis also plays an important role in protein trafficking 
by regulating the release of waste products from the cell, and has 
been shown to be altered in normal retinal aging and AMD.9,34 
Indeed, drusen deposits characteristically found in patients 
with AMD show high levels of the exosome proteins CD63 and 
LAMP2.9,34 Following validation of our exosome isolation pro-
tocol using the exosome marker CD63 (Supplementary Figure 
S3A,B), media was collected from the apical and basal chambers 
of transwells containing monolayers of RPE. Thereafter, quanti-
fication of total protein revealed increased secretion of exosomes 
on both the apical and basal sides of BD hiPSC-RPE relative 
to control cultures (BD-2 versus Ctr-2 apical: 2.12 ± 0.52-fold, 
P = 0.06 and basal: 1.49 ± 0.23-fold, P < 0.05; BD-1 versus Ctr-1 
apical: 2.13 ± 0.23, P = 0.008 and basal: 1.16 ± 0.04, P value not 
significant; Figure 2e). Subsequent comparisons demonstrated 
higher levels of CD63 in apically and basally secreted exosomes 
collected from BD versus control hiPSC-RPE (Figure 2f). 
Ponceau staining of western blot membranes also revealed 
higher levels of total protein in exosome samples collected 
from apical and basal media of BD versus control hiPSC-RPE 
(Supplementary Figure S3C). Together, these results suggest 
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that perturbations in proteolytic pathways could contribute 
to the delayed POS degradation seen in BD hiPSC-RPE, with 
enhanced exocytosis occurring as a possible compensatory 
response to combat retained intracellular waste.
Examination of autophagy and lysosomal function in 
BD hiPSC-RPE
Given that ubiquitination can also modulate autophagy-mediated 
protein breakdown,35 and both autophagy and lysosomal function 
play an important role in POS phagocytosis and degradation in 
RPE cells,7,15,36 we next looked at the expression and localization of 
key proteins and enzymes in these two pathways. No difference in 
the protein expression of LC3 I or LC3 II, or in the LC3 II/I ratio, 
was observed between BD and control hiPSC-RPE (BD-1 versus 
Ctr-1: 1.01 ± 0.23; BD-2 versus Ctr-2: 0.78 ± 0.30; Figure 3a,b). 
Furthermore, no differences in the expression of P62 (also called 
SQSTM1), a marker of autophagic flux, or BECN1, an autophagy 
modulator, were seen between BD and control hiPSC-RPE (P62, 
BD-1 versus Ctr-1: 0.99 ± 0.22-fold; BD-2 versus Ctr-2: 1.12 ± 0.09-
fold; BECN1, BD-2 versus Ctr-2: 1.32 ± 0.33-fold; Supplementary 
Figures S4A,B and S5A,B). Localization of the lysosomal protein 
LAMP1 by immunocytochemistry was also similar between BD 
and control hiPSC-RPE (Figure 3c), as was the protein expres-
sion of both LAMP1 and LAMP2 (LAMP1, BD-1 versus Ctr-1: 
1.19 ± 0.13-fold; BD-2 versus Ctr-2: 0.76 ± 0.08-fold; LAMP2, 
BD-1 versus Ctr-1: 1.33 ± 0.04-fold; BD-2 versus Ctr-2: 0.98 ± 0.05-
fold; Figure 3c and Supplementary Figures S4C and S5C,D). 
Western blot and immunohistochemical analyses of CTSD, a 
lysosomal enzyme involved in POS degradation by RPE,37,38 and 
CTSB revealed no differences in their localization and expression 
between BD and control hiPSC-RPE (CTSD, BD-1 versus Ctr-1: 
0.91 ± 0.06-fold; BD-2 versus Ctr-2: 0.91 ± 0.05-fold; CTSB, BD-1 
versus Ctr-1: 1.33 ± 0.04-fold; BD-2 versus Ctr-2: 0.98 ± 0.05-fold; 
Figure 3d and Supplementary Figure S5E,F).
Figure 1  Accumulation of POS-derived autofluorescent material and oxidized proteins in BD hiPSC-RPE. (a) Representative light microscopic 
images of control and BD hiPSC-RPE (Ctr-1: sibling of BD-1; Ctr-2: sibling of BD-2). (b) Control and BD hiPSC-RPE were fed POS daily for 1–1.5 
months followed by daily washes for two weeks. Representative confocal microscopic images showing accumulation of autofluorescent (red and 
green channels) material in Ctr-1 and BD-1 hiPSC-RPE. (c) Baseline carbonylated protein levels in BD hiPSC-RPE normalized to respective control 
hiPSC-RPE cultures. (d) Expression of genes associated with oxidative stress in BD hiPSC-RPE cultures normalized to their respective controls. Bars = 50 
μm. *P < 0.05. BD, Best disease; hiPSC, human induced pluripotent stem cell; POS, photoreceptor outer segment; RPE, retinal pigment epithelium.
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Lastly, we assessed lysosomal pH in hiPSC-RPE using a com-
mercially available dye, lysosensor yellow-blue. As with the afore-
mentioned experiments, no difference in baseline lysosomal pH 
was seen in BD versus control hiPSC-RPE (BD-1: 4.25 ± 0.08 ver-
sus Ctr-1: 4.38 ± 0.10; BD-2: 4.82 ± 0.10 versus Ctr-2: 4.87 ± 0.11; 
Supplementary Figure S4D). As a control, we measured lyso-
somal pH in human fetal RPE, hfRPE, (4.91 ± 0.01) in the presence 
or absence of the alkalinizing agent chloroquine, which signifi-
cantly increased lysosomal pH (to 5.44 ± 0.18; Supplementary 
Figure 4D). Based on these results, there appears to be no detect-
able dysfunction of autophagy or lysosomal protein degradation 
pathways in our BD hiPSC-RPE models.
Modulation of POS degradation in hiPSC-RPE
If altered protein degradation contributes to the delay in POS 
breakdown observed in BD hiPSC-RPE, we should be able to 
mimic this POS processing defect in normal hiPSC-RPE by tar-
geting protein degradation pathways. Control hiPSC-RPE cells 
were treated with bafilomycyin A1 (BafA1), a V-ATPase inhibi-
tor that affects autophagosome-lysosome fusion,26,27 and then fed 
unlabeled POS for 2 hours. After washing, the amount of RHO 
protein present in the hiPSC-RPE cells was quantified by Western 
blot analysis at 0 and 24 hours (Figure 4a). No difference was 
observed in RHO levels between untreated and BafA1-treated 
control hiPSC-RPE at 0 h (lane 1 versus lane 2). However, at the 
Figure 2 Comparison of POS degradation, proteasome function, and exosome secretion in control versus BD hiPSC-RPE. (a) Schematic (upper 
panel) depicting the protocol used to assess uptake and degradation of the POS-specific protein, RHO, in hiPSC-RPE. Western blot analysis (lower 
panel) showing the amount of RHO present in Ctr-2 versus BD-2 hiPSC-RPE at 0, 4, 24, 48, and 120 hours after 2 hour POS feeding (20 POS/RPE cell). 
(b) Confocal microscopic image showing the localization of total UB protein (poly-UB + free-UB) in Ctr-2 and BD-2 hiPSC-RPE. (c,d) Representative 
western blot image (c) and quantification (d) of free-UB and poly-UB in control versus BD hiPSC-RPE. Data in panel d is expressed as a fraction of free-
UB or poly-UB relative to ACTIN (ACTN) in each sample, normalized to control hiPSC-RPE. (e) Quantification of exosome release from Ctr-2 versus 
BD-2 hiPSC-RPE into apical and basal media. (f) Western blot comparing CD63 levels in exosome samples isolated from the apical and basal media 
of Ctr-2 and BD-2 hiPSC-RPE. Bar = 20 μm. ACTN = ACTIN control. *P < 0.05. BD, Best disease; DAPI, 4′,6-diamidino-2-phenylindole; hiPSC, human 
induced pluripotent stem cell; POS, photoreceptor outer segment; RHO, RHODOPSIN; RPE, retinal pigment epithelium; UB, ubiquitin. 
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24-hour time point, RHO levels in untreated control hiPSC-RPE 
were lower than in BafA1-treated control hiPSC-RPE (lane 3 ver-
sus lane 4). No difference in the levels of ACTIN (ACTN), a load-
ing control, was observed between untreated and BafA1-treated 
hiPSC-RPE (Figure 4a).
We next sought to determine if POS breakdown could be 
enhanced in normal hiPSC-RPE with therapeutically relevant con-
centrations of VPA, an FDA-approved drug that has been shown to 
augment protein degradation.39–44 After feeding cells with unlabeled 
POS as described above, RHO levels at 0 hours were higher in some 
200 or 500 μmol/l VPA-treated hiPSC-RPE cultures compared to 
untreated control hiPSC-RPE, suggesting possible enhanced uptake 
of POS in the presence of VPA (Figure 4b, lanes 1–3). However, 
even with higher initial RHO content, RHO levels 24 hours after 
feeding were significantly lower in control hiPSC-RPE treated with 
500 μmol/l VPA compared to untreated or 200 μmol/l VPA-treated 
control hiPSC-RPE (Figure 4b, lanes 4–6; Figure 4d). We also inves-
tigated whether VPA could counteract the effect of BafA1 treatment 
on the rate of RHO degradation in control hiPSC-RPE (Figure 4c). 
Consistent with results shown in Figure 4a, control hiPSC-RPE cells 
treated with BafA1 showed higher amounts of POS 24 hours after 
feeding compared to untreated hiPSC-RPE cells (lane 5 versus lane 
4). VPA (500 μmol/l) treatment significantly reduced the negative 
effect of BafA1 on RHO degradation in control hiPSC-RPE cells 
(Figure 4c; lane 6 versus lane 5). Quantification of the effect of VPA 
and BafA1 on POS breakdown in control hiPSC-RPE, as measured 
by RHO levels at 24 hours relative to 0 hours, is shown in Figure 4d. 
These experiments indicate that the rate of POS processing in nor-
mal hiPSC-RPE can be modulated with drugs that affect intracel-
lular protein degradation.
Regulation of POS degradation by pharmacological 
treatments in BEST1 mutant models
Although VPA could increase RHO degradation in untreated 
and BafA1-treated control hiPSC-RPE, it remained to be seen 
if drug treatment could similarly accelerate POS breakdown in 
RPE harboring mutations in BEST1. Ideally, an in vivo model is 
employed for such analyses; therefore, we first carried out stud-
ies to determine whether VPA can be used as an experimental 
treatment in a canine model of autosomal recessive bestrophi-
nopathy.45–47 Importantly, variation in age of onset, clinical 
manifestations, and disease progression have been observed in 
dogs with BEST1 mutations, similar to the inter- and intrafa-
milial variability in the phenotypic expression reported in BD 
patients.48–50 Following a 3-week VPA dose-escalation trial (see 
Supplementary Information for details) that did not reveal any 
adverse effects related to VPA administration, a maximum dose 
of 120 mg/kg twice daily51 was given to older R25X- or P463fs-
affected dogs with established disease. After a 12-week trial, no 
changes in disease appearance and unaltered disease progression 
were observed (data not shown). In contrast, VPA treatment in 
younger BEST1 mutant dogs prior to ophthalmoscopically vis-
ible lesions (Figure 5a) retarded severity and progression of the 
disease (Figure 5b,c). Although all VPA-treated dogs developed 
BD symptoms, the disease was more advanced in the untreated 
group progressing to stage 3 (an early pseudohypopyon phase) in 
comparison to the VPA-treated eyes reaching only stage 2 (vitelli-
form; Figure 5c). To determine if adequate VPA blood levels were 
achieved, we ran pharmacokinetics studies in all VPA-treated 
dogs. While the mean VPA elimination half-life in humans is ~16 
hours,52 we confirmed a previously published study that the drug 
Figure 3 Expression and localization of autophagy and lysosomal proteins in control versus BD hiPSC-RPE. (a,b) Representative western blot image (a) 
and quantification (b) showing expression levels of the autophagy markers LC3 I and LC3 II and the LC3 II/I ratio in BD hiPSC-RPE normalized to their respec-
tive control hiPSC-RPE. (c) Localization of the lysosomal protein LAMP1 (green) and the tight junction protein ZO-1 (red) by confocal microscopy in Ctr-2 and 
BD-2 hiPSC-RPE. (d) Western blot analyses comparing the expression of the lysosomal enzymes CTSD and CTSB in control and BD hiPSC-RPE. Bar = 20 μm. 
ACTN = ACTIN control. BD, Best disease; DAPI, 4′,6-diamidino-2-phenylindole; hiPSC, human induced pluripotent stem cell; RPE, retinal pigment epithelium.
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is eliminated much more rapidly in dogs.53 While we could consis-
tently achieve therapeutic plasma levels in both adults and young 
dogs, these were not sustained, and fell to nontherapeutic levels 
within 4 hours (Figure 6). Higher VPA doses or more frequent 
dosing were not allowed due to concerns regarding drug toxicity 
in dogs.
Given the limitations of the canine bestrophiniopathy model, 
we returned to our hiPSC-RPE model to test the effects of VPA on 
POS degradation. We fed unlabeled POS to untreated and VPA-
treated BD hiPSC-RPE cells for 2 hours and measured RHO levels 
at 0 and 24 hours after washing as described earlier. Degradation 
of RHO over this time period was greater in VPA-treated com-
pared to untreated BD hiPSC-RPE (Figure 7a, 500 μmol/l VPA-
treated: lane 2 versus lane 4, untreated: lane 1 versus lane 3). 
Although VPA could be acting through a variety of mechanisms, 
we found that VPA treatment increased autophagy after POS feed-
ing as measured by the LC3 II/I ratio (Supplementary Figure S6). 
Therefore, in an attempt to augment the VPA effect, we exposed 
BD hiPSC-RPE to RAPA, an autophagy inducer,28 both in the 
absence and presence of VPA. Treatment with either 100 nmol/l 
RAPA or 500 μmol/l VPA resulted in reduced RHO levels in 
POS-fed BD hiPSC-RPE at 24 hours (Figure 7b; VPA: 0.45 ± 0.09, 
P < 0.05, RAPA: 0.59 ± 0.09, P = 0.12). However, combinatorial 
therapy with 500 μmol/l VPA + 100 nmol/l RAPA caused a much 
greater reduction in RHO levels at 24 hours than either treatment 
alone (Figure 7b; 0.14 ± 0.04, P < 0.005). Of note, the synergis-
tic effect of RAPA was not tested in vivo, as it is known to cause 
severe side effects in dogs.54 Regardless, the ability to rescue the 
phenotype of delayed POS degradation in BD hiPSC-RPE with 
both VPA and RAPA provides further evidence that impaired pro-
teolytic ability may contribute to the disease pathology.
Lastly, we next measured accumulation of autofluorescent 
material in BD and control hiPSC-RPE after chronic POS feed-
ing with and without daily treatment with 500 μmol/l VPA. VPA 
decreased the amount of retained autofluorescent material after 
1.5 months of POS feeding in BD hiPSC-RPE, but not in control 
hiPSC-RPE (Figure 7c,d and Supplementary Figure S7a,b). Of 
note, no autofluorescence accumulation was seen in BD or control 
Figure 4 Pharmacological modulation of POS degradation in control hiPSC-RPE. (a–c) Representative western blot analyses showing the amount of 
the POS protein RHO present in control hiPSC-RPE at 0 and 24 hours after POS feeding in the presence or absence of drug. Drug treatments included 
bafilomycin (BafA1, 100 nmol/l) (a), valproic acid (VPA, 200 and 500 μmol/l) (b), and BafA1 (100 nmol/l) + VPA (500 μmol/l) (c). (d) Quantification of 
RHO levels 24 hours after POS feeding in control hiPSC-RPE (Ctr-1 + Ctr-2) treated with VPA (200 and 500 μmol/l), BafA1 (100 nmol/l), or VPA (500 μmol/l) 
+ BafA1 (100 nmol/l). The percentage of RHO remaining at 24 hours relative to untreated control hiPSC-RPE is presented. ACTN = ACTIN control. *P < 
0.05; **P < 0.01. hiPSC, human induced pluripotent stem cell; POS, photoreceptor outer segment; RHO, RHODOPSIN; RPE, retinal pigment epithelium.
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hiPSC-RPE cells in the absence of POS feeding (Figure 7c and 
Supplementary Figure 7a). Altogether, these data indicate that 
POS processing in BD hiPSC-RPE can be enhanced with drugs 
that act at least in part by increasing protein degradation.
DISCUSSION
Our results demonstrate that POS degradation can be augmented 
pharmacologically in control and BD hiPSC-RPE. We also show 
that the delayed POS degradation observed in BD hiPSC-RPE can 
be mimicked in control hiPSC-RPE by administering a proteo-
lytic inhibitor, bafilomycin A1 (BafA1). In both BD hiPSC-RPE 
and control hiPSC-RPE treated with BafA1, the POS degradation 
defect can be rescued with VPA, an FDA-approved drug that has 
been shown to increase cellular proteolysis.39–41 Daily VPA treat-
ment also reduced accumulation of autofluorescent material in 
BD hiPSC-RPE after chronic POS feeding.
We further found that the combination of VPA and RAPA 
was considerably more effective at increasing the rate of POS 
degradation in BD hiPSC-RPE than VPA alone. The synergism 
observed between VPA and RAPA, two drugs that can increase 
proteolysis,28,39–41 suggests a possible link between abnormal pro-
tein degradation and defective POS handling in BD hiPSC-RPE. 
Interestingly, animal studies have demonstrated that HDAC 
inhibitors, including VPA, are protective in some forms of reti-
nal degeneration and after ischemic retinal and cardiac injury, 
with one proposed mechanism of action being induction of auto-
phagy.55–58 However, both VPA and RAPA are known to exhibit 
pleiotropic effects, so it remains possible that their influences on 
proteolytic pathways and POS degradation are indirect.
While this study primarily examined whether drugs could 
mitigate the development of cellular pathology in BD hiPSC-RPE, 
pharmacological intervention may also be of benefit in later stages 
of disease. While no improvement was seen in established retinal 
lesions after treatment of adult BEST1 mutant canines with VPA, 
the effects of the drug may have been dampened by its rapid clear-
ance. Nevertheless, given the option, it is preferable to slow or halt 
disease progression rather than attempt to reverse chronic cell 
and/or tissue damage. The fact that VPA has a well-established 
safety profile59 and is routinely used long term in pediatric and 
adult patients makes it a particularly attractive therapeutic for BD, 
a disease that is frequently diagnosed in childhood before signifi-
cant vision loss occurs.60,61 (By contrast, RAPA has a more promi-
nent side effect profile and thus may not be an optimal adjunctive 
drug.62) In the present study, delayed disease progression was 
observed in a small cohort of BEST1 mutant canines who were 
treated early and continuously with VPA, even though the daily 
therapeutic window was brief. Given the observed effects of VPA 
in BD hiPSC-RPE and its known safety profile in humans, further 
investigation into its therapeutic value may be warranted despite 
the absence of a suitable in vivo efficacy model.
Impairment of protein degradation machinery can occur dur-
ing normal aging and in MDDs,10,63,64 where it correlates with the 
accumulation of partially digested POS in RPE cells.1,3,38,64 Thus, 
our findings in BD hiPSC-RPE could result from general distur-
bances in proteolysis. Baseline examination of protein degrada-
tion pathways and exocytosis revealed a greater oxidized protein 
burden, decreased free-UB levels, and increased exocytosis in 
BD hiPSC-RPE. Both increased protein oxidation and decreased 
free-UB levels can be a consequence of dysfunctional or overtaxed 
proteolytic pathways, whereas increased exocytosis may be an 
adaptive response to the excess material within the cell.
While the function and localization of BEST-1 protein remain 
the topic of debate, recent publications of the X-ray crystal 
Figure 5 Evaluation of VPA treatment in the canine BEST1 mutant 
model. (a) Baseline ophthalmic and cSLO evaluations performed on 
two 3-month-old littermates affected with c.C73T/p.R25X mutation 
in the canine BEST1 gene. (b) Clinical manifestation of BD symptoms 
documented during retinal exam 8 weeks post-VPA treatment (left 
panel: treated sibling) versus untreated sibling control (right panel). BD 
lesions limited to the canine fovea-like region83 are denoted by arrow-
heads (red). (c) cSLO/SD-OCT endpoint evaluation of BD lesions (left 
panel: treated sibling) versus untreated sibling control (right panel). 
BD lesions are documented by in vivo imaging in NIR and FAF modes, 
and on the cross-sectional OCT scans (arrows). Note the autofluores-
cent debris accumulating in pseudohypopyon lesion (OD, FAF) of the 
untreated dog. BD, Best disease; cSLO, confocal scanning laser ophthal-
moscopy; FAF, fundus autofluorescence; NIR, near-infrared; SD-OCT, 
spectral domain optical coherence tomography; OD, right eye; OS, left 
eye: applies to all panels; VPA, valproic acid.
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Figure 6 VPA pharmacokinetic profile during continued treatment in canine BEST1 mutant model. VPA serum levels were determined for all 
BD-affected (n = 4) and control (n = 1) dogs. Total plasma VPA concentrations reached therapeutic range within 2 hours postadministration of a 
single dose and rapidly declined within 3 hours thereafter (1 PM, weeks 9–12). Baseline (untreated) levels were present by the 6 AM time period of the 
day following dosing (weeks 2–12). The error bars represent SD of the measurements for n ≥ 3 per time point. BD, Best disease; VPA, valproic acid.
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Figure 7 Pharmacological modulation of POS degradation in BD hiPSC-RPE. (a) Representative western blot analysis comparing the amount of 
the POS protein RHO in untreated and VPA-treated (500 μmol/l) BD hiPSC-RPE at 0 and 24 hours after POS feeding. (b) Quantification of RHO levels 
24 hours after POS feeding in untreated versus treated (500 μmol/l VPA, 100 nmol/l RAPA, or 500 μmol/l VPA + 100 nmol/l RAPA) BD hiPSC-RPE 
(BD-1 + BD-2). (c) Confocal microscopic images showing accumulation of autofluorescent material (red channel) in untreated (left panels) and VPA-
treated (500 μmol/l; right panels) BD-2 hiPSC-RPE in the presence (lower panels) or absence (upper panels) of daily POS feeding for 1.5 months. 
(d) Quantification of average autofluorescence levels in untreated and VPA-treated BD-2 hiPSC-RPE after daily POS feeding for 1.5 months (note log 
scale on y-axis). Bar = 50 μm. ACTN = ACTIN control. *P < 0.05; **P = 0.001. BD, Best disease; hiPSC, human induced pluripotent stem cell; POS, 
photoreceptor outer segment; RAPA, rapamycin; RHO, RHODOPSIN; RPE, retinal pigment epithelium; VPA, valproic acid. 
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structures of bacterial and avian Best-1 point to a role as a cal-
cium-activated chloride channel.65,66 Significant evidence also 
links BEST-1 to the trafficking of calcium from endoplasmic 
reticulum stores.67,68 Therefore, the abnormalities in proteolysis 
and POS handling found in BD hiPSC-RPE may be secondary to 
subtle disturbances in cellular ion homeostasis. Along this line of 
reasoning, calcium is known to regulate POS processing,69–71 and 
changes in calcium and chloride homeostasis can influence pro-
teolytic pathways.72–76
A limitation of in vitro RPE models as systems to evaluate 
POS handling is that they do not replicate the intricacies of the 
photoreceptor–RPE complex in vivo. This shortcoming might 
have affected our ability to consistently document defects in bind-
ing and uptake of POS in BD hiPSC-RPE, although such effects 
were occasionally observed (Figure 2a).2 Therefore, although 
delayed POS degradation appears to contribute to the BD hiPSC-
RPE phenotype, other important effects on POS handling, such 
as phagocytosis, may have escaped definitive detection in our 
assays. Regardless, the finding that VPA can accelerate the clear-
ance of ingested POS in hiPSC-RPE, with or without concurrent 
enhancement of POS uptake (Figure 7a), holds promise for its 
ability to beneficially affect the BD phenotype.
In summary, we have shown that modulating proteolytic 
machinery in BD and control hiPSC-RPE can influence the rate of 
POS degradation. Our findings have implications for drug-based 
therapy of BD and other MDDs that demonstrate accumulation 
of POS breakdown products in RPE. In addition, we call atten-
tion to a situation in which a hiPSC-based model may be prefer-
able to available animal models for drug efficacy testing. A similar 
scenario recently arose during development of a gene therapy 
strategy for choroideremia, a rare inherited retinal degenerative 
disorder that also affects RPE.77 Since no suitable animal model 
of choroideremia exists, efficacy was established exclusively using 
patient-specific hiPSCs, which led in part to approval for a clini-
cal trial.
The utility of hiPSC models for screening pharmaceuticals 
is perhaps greatest for diseases like BD that display extensive 
genotype-phenotype heterogeneity.48–50,78–80 Instead of searching 
for - or attempting to create - animal models for each pathogenic 
mutation (e.g., BD has >100 known disease-causing mutations), 
hiPSCs can be made relatively quickly and inexpensively from 
individual patients, allowing direct clinical correlation and “per-
sonalized” drug testing. BD hiPSC-RPE models are also conve-
nient platforms for high throughput drug screening, which could 
lead to combinatorial treatment approaches targeting other cel-
lular pathways affected in this disease (e.g., chloride and calcium 
homeostasis). However, there are clear disadvantages of in vitro 
systems for drug testing as well, including their inability to evalu-
ate bioavailability or effects on vision. Thus, at minimum, safety 
and bio-distribution studies require use of appropriate animal 
models regardless of how efficacy is established.
MATERIALS AND METHODS
hiPSC production, passage, and differentiation to RPE fate. Fibroblasts 
obtained from skin biopsies were reprogrammed to obtain hiPSCs as 
previously described2 whereupon they were maintained on either mouse 
embryonic feeder (MEF) feeder layers using our previously established 
protocol, or on Matrigel (WiCell, Madison, WI).2,81 hiPSCs on Matrigel 
were cultured in commercially available TeSR media (Wicell), and any 
areas of spontaneous cellular differentiation were mechanically removed. 
hiPSCs were passaged every 3 to 4 days and differentiated to RPE as previ-
ously described.2,81 Briefly, hiPSC colonies were lifted with dispase (2 mg/
ml) and put in embryoid body medium (EBM) (DMEM/F12, 20% KOSR, 
1% MEM nonessential amino acids, 1 mmol/l l-glutamine, and 0.1 mmol/l 
β-ME) to grow as suspended embryoid bodies (EBs). EBs were transi-
tioned to neural induction medium (NIM) (DMEM/F12, 1% N2 supple-
ment, MEM nonessential amino acids, and 2 μg/ml heparin) over days 1, 
2, and 3 by introducing media containing EBM/NIM in ratios of 3:1, 1:1, 
and 1:3, respectively. By day 4, the media contained NIM alone. On day 7, 
suspended EB aggregates in NIM were plated onto laminin-coated culture 
plates to allow the EBs to attach to the culture plate; thereafter, cell aggre-
gates were grown for an additional 10 days in NIM. On day 16, NIM was 
replaced with retinal differentiation medium (RDM) (DMEM/F12 (3:1), 
2% B27 supplement (without retinoic acid), and penicillin streptomycin). 
Adherent cultures of cells in RDM were maintained until large patches of 
pigmented RPE cells appeared (~day 60–90). Pigmented RPE cell clus-
ters were then manually dissected under a microoscope, dissociated with 
Trypsin-EDTA (0.05%), and plated onto extracellular matrix-coated trans-
well inserts (Corning Costar, Corning Incorporated, Corning, NY) in 
RDM + 10% FBS. The media was switched after 2 days to RDM + 2% FBS 
and cells were grown until confluent. After confluency was reached, cells 
were maintained in RDM to allow RPE cells to mature. Of note, hiPSC 
lines from two independent clones derived from each individual (Ctr-1, 
Ctr-2, BD-1, and BD-2) were used in this study.
Quantification of oxidized proteins. RPE cells were lysed in 1× phosphate-
buffered saline (PBS) containing protease inhibitor cocktail (PI; Sigma, St 
Louis, MO). Protein samples thus obtained were treated with DNase I 
(Life Technologies, Grand Island, NY) and quantified using the Bio-Rad 
DC protein assay (Bio-Rad, Hercules, CA). Levels of oxidized proteins 
were evaluated using an ELISA kit for quantification of protein carbonyls 
(Cat. # STA 310; Cell Biolabs, San Diego, CA) according to manufacturer’s 
instructions.
Quantitative RT-PCR. Total RNA was extracted using either the RNeasy 
Mini Plus Kit (Qiagen, Valencia, CA) or Arcturus PicoPure RNA Isolation 
Kit (Life Technologies), and cDNA was synthesized (iScript cDNA 
Synthesis Kit Biorad, Hercules, CA) according to manufacturer’s instruc-
tions. Extracted RNA was subjected to DNase I treatment to remove any 
genomic DNA contamination prior to cDNA synthesis. Quantitative 
RT-PCR (qRT-PCR) experiments were carried out using cDNA samples, 
gene-specific primers (Supplementary Table S2), SsoAdvanced SYBR 
Green Supermix (Bio-Rad), and a Bio-Rad C1000 thermal cycler (40 
cycles). Results were compiled and analyzed using Bio-Rad CFX software 
and Microsoft Excel.
Western blotting. Total protein was isolated by lysing cells in RIPA buf-
fer (Pierce, Rockford, IL) containing protease inhibitor (PI) and quantified 
using a Biorad DC protein assay (Bio-Rad). Protein lysates (5–20 μg) were 
denatured in 1× Laemelli + 5% β-ME buffer and separated on either a 10, 
12, or 4–20% Tris–Cl gradient gel. Proteins from the gel were transferred 
onto PVDF-licor membranes, stained with Ponceau, and incubated with 
blocking buffer (Licor Biosciences, Lincoln, NE) for 1 hour at room temper-
ature. Membranes were then incubated overnight at 4 °C with the following 
primary antibodies: rabbit anti- LC3 (1:200; Novus Biologicals, Littleton, 
CO), mouse anti-SQSTM1 (also referred to as anti-P62) (1:400; Santa 
Cruz Biotechnology, Dallas, TX), mouse anti-LAMP1 (1:500; Santa Cruz 
Biotechnology), mouse anti-LAMP2 (1:500; Santa Cruz Biotechnology), 
goat anti-CTSD (1:500; Santa Cruz Biotechnology), goat anti-CTSB (1:500; 
Santa Cruz Biotechnology), rabbit anti-UB (1:1,000; Dako, Carpinteria, 
CA), rabbit anti-UB Lys63 (Millipore, Billerica, MA), rabbit anti-UB 
Lys48 (1:1,000; Millipore), mouse anti-CD63 (1:500; Novus Biologicals), 
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goat anti-APOE1 (1:500; Millipore), mouse anti-RHO (1:500; Millipore), 
and/or goat anti-ACTN (1:500; Santa Cruz Biotechnology). The following 
day, blots were washed four times in wash buffer (PBS + 0.1% tween) and 
incubated for 1 hour at room temperature in appropriate secondary anti-
bodies (Licor Biosciences). Following incubation, blots were washed four 
times, and proteins were visualized on an Odyssey Infrared Imager (Licor). 
In most experiments, individual western blots were stripped (stripping buf-
fer, LICOR) and probed up to three times with different primary antibodies. 
Of note, all quantitative analyses of the western blot data were carried out 
using image acquisition software (Licor Odyssey 3.0 and/or Image Studio).
Immunohistochemistry. hiPSC-RPE cells were washed in ice-cold PBS, 
fixed in 4% paraformaldehyde on ice for 30 minutes and incubated in 
blocking solution (10% normal donkey serum and 0.01% Triton X-100 in 
PBS) for 1 hour at room temperature. Cells were then incubated overnight 
at 4 °C in the following primary antibodies: rabbit anti-ZO-1 (1:100; Life 
Technologies), mouse anti-SQSTM1 (also referred to as anti-P62) (1:200; 
Santa Cruz Biotechnology), goat anti-CTSD (1:200; Santa Cruz), mouse 
anti- LAMP1 (1:200; Santa Cruz), rabbit anti-UB (1:150; Dako), and mouse 
anti-CD63 (1:200; Novus Biologicals). The next day, cells were washed 
three times in wash buffer (0.01% Triton X-100 in PBS) and incubated for 
1 hour in Alexa-labeled secondary antibodies (1:500; Life Technologies). 
Cells were then stained with 4′,6-diamidino-2-phenylindole (DAPI) for 
30 minutes, washed three times, and mounted using Prolong Gold (Life 
Technologies). Fluorescence imaging was carried out on a Nikon C1 and/
or Nikon A1 confocal microscope (Nikon Instruments, Melville, NY).
Proteasome activity. Pigmented monolayers of hiPSC-RPE grown on 
trans wells were dissociated with Trypsin-EDTA (0.05%) and the amount of 
chymotrypsin-like protease activity was measured using the Proteasome-
Glo Chymotrypsin-Like cell-based assay (Promega, Madison, WI) in 
accordance with the manufacturer’s instructions. Briefly, dissociated cells 
resuspended in PBS were incubated with a mixture of chymotrypsin-like 
assay substrate (Suc-LLVY-glo) and luciferase reagent for 30 minutes 
at room temperature. Thereafter, luminescence was measured using a 
Glomax luminometer (Promega).
Phagocytosis assay. hiPSC-RPE grown as pigmented monolayers on 
trans wells were used for phagocytosis assays as previously described.2 In 
brief, for each experiment, hiPSC-RPE cells from each treatment group 
were incubated with an equivalent amount of unlabeled bovine POS for 
2 hours. Afterward, 1× PBS was used to vigorously wash hiPSC-RPE cells 
4–5 times to remove any POS that remained on the surface of the transwell 
(designated as the 0 hour time point), and then the RPE was harvested for 
protein isolation. At 0, 4, 24, 48, and 120 hour time points after POS feeding 
and washing, hiPSC-RPE cells were washed an additional two times with 
1× PBS. Isolated proteins were utilized in western blotting experiments and 
probed for the POS-specific protein, RHO. hiPSC-RPE cells that had not 
been POS-fed served as negative controls. Of note, hiPSC-RPE belonging 
to different treatment groups were fed POS at the same time (either in the 
morning or early afternoon), and all subsequent processing (e.g., washing, 
sample collection, protein isolation, and western blotting) for each group 
was performed in parallel. The bovine POS used in these experiments were 
isolated either in the lab using a previously described protocol2 or obtained 
commercially (Invision Biosciences, Seattle, WA).
Lysosomal pH measurement. Pigmented monolayers of hiPSC-RPE and 
hfRPE cultured on transwells were employed for measurements of lyso-
somal pH using the commercially available dye, lysosensor yellow-blue 
(Life Technologies), as previously described.82 The lysosome perturbation 
compound, chloroquine (100 μmol/l), was used as a positive control in 
these experiments.
Exosome isolation and quantification. For exosome isolation, mature 
monolayers of hiPSC-RPE grown on transwells were incubated in filtered 
RDM overnight. The next day, media was collected separately from the 
apical and basal compartments of the transwell chambers and replaced 
with fresh filtered RDM. PI was added to the collected media samples, 
which were immediately stored at −80 °C until analyzed further. Media 
collected daily from the apical and basal chambers for a total period of 
15–30 days was used for exosome isolation by differential centrifuga-
tion. Briefly, media was centrifuged sequentially at 300 × g for 10 min-
utes, 2,000 × g for 10 minutes, and 10,000 × g for 30 minutes. After each 
centrifugation, supernatant was collected and the pellet containing cells 
and/or cellular debris was discarded. The final supernatant thus obtained 
was subjected to a final centrifugation at 100,000 × g for 60–75 minutes 
to pellet exosomes and contaminating proteins. Exosome samples were 
then washed 1× in PBS and re-centrifuged to obtain purified exosomes. 
Total protein was extracted from freshly isolated exosomes, quantified, and 
visualized via western blotting as described above. Of note, we validated 
our exosome isolation protocol by quantifying the amount of CD63, an 
exosome marker, in protein samples from cell lysates versus purified exo-
somes. Western blot analysis revealed higher levels of CD63 in exosome 
samples compared to equivalent whole cell lysate samples (Supplementary 
Figure S2B). Furthermore, we performed western analysis on undiluted 
versus diluted exosome samples to validate the use of the CD63 antibody 
for quantitative analysis (Supplementary Figure S2B).
VPA trial in canine BD model. All dogs were bred and maintained at 
the University of Pennsylvania Retinal Disease Studies Facility (RDSF), 
Kennett Square, Pennsylvania, and supported by facility grants from FFB 
and NEI/NIH EY06855. The studies were carried out in strict accordance 
with the recommendations in the Guide for the Care and Use of Laboratory 
Animals of the NIH, the USDA’s Animal Welfare Act and Animal Welfare 
Regulations, and complied with the ARVO Statement for the Use of 
Animals in Ophthalmic and Vision Research. The protocol was approved 
by the Institutional Animal Care and Use Committee of the University of 
Pennsylvania (IACUC Protocol #803422). Adult (n = 2; 1 and 5 years) and 
young (n = 4; 3 months) dogs carrying homozygous c.C73T/p.R25X or 
c.1388delC/p.P463fs mutation in BEST1 and a wild-type control (n = 1; 4 
years of age) were used. Both mutations result in identical disease pheno-
type and progression.45,46 Dogs were treated with an oral solution of VPA 
(Pharmaceutical Assoc, Greenville, SC) administered twice daily, receiv-
ing doses of 30- (week 1), 60- (week 2), or 120 mg/kg (week 3) during the 
dose-escalation study conducted on two adult affected and the wild-type 
control, and continued at 120 mg/kg twice daily for the next 12 weeks.51 
Blood samples were collected prior to VPA trial, and then every week dur-
ing the VPA treatment at selected time points. Evaluation of VPA plasma 
levels was performed by the Diagnostic Center for Population and Animal 
Health at Michigan State University, East Lansing, Michigan. Ophthalmic 
examinations, including biomicroscopy, indirect ophthalmoscopy, and 
fundus photography, were conducted on a weekly basis. Noninvasive 
en face and cross-sectional imaging using confocal scanning laser ophthal-
moscopy and spectral domain optical coherence tomography (SD-OCT) 
was performed under general anesthesia as described previously47,83 prior 
to and after completion of the study. Post-acquisition processing of OCT 
data was performed on Heidelberg Eye Explorer software (version 1.7.0.0; 
Heidelberg Engineering GmbH, Heidelberg, Germany).
Statistics. Data are expressed as mean ± SEM and compared using 
Student’s t-test. Data in specific experiments were subjected to F-test to 
determine the appropriate Student’s t-test parameters. Significance was 
assigned for P values less than 0.05. Of note, in Figure 4, significance 
for VPA + BafA1 was determined by Student’s t-test against the BafA1-
treated group, and in Figure 7, data were normalized to the percentage 
of RHO remaining at 24 hours in untreated BD hiPSC-RPE. All hiPSC-
RPE experiments were performed on n ≥ 3 independent cultures with the 
exception of the chronic (>1–2 month) POS feeding experiments ± VPA 
treatment, in which two independent hiPSC-differentiation runs were 
performed with 2–3 separate samples per condition (untreated, VPA only, 
POS only, and POS + VPA).
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SUPPLEMENTARY MATERIAL
Figure S1. Autofluorescence accumulation and RHO degradation in 
control vs. BD hiPSC-RPE.
Figure S2. Proteasomal activity and quantification of free-UB and 
poly-UB in control vs. BD hiPSC-RPE.
Figure S3. Comparison of CD63 localization and exosome protein 
levels in control and BD hiPSC-RPE.
Figure S4. Localization and expression of autophagy and lyso-
somal proteins and quantification of lysosomal pH in control vs. BD 
hiPSC-RPE.
Figure S5. Quantitative analysis of autophagy and lysosomal protein 
expression in control vs. BD hiPSC-RPE.
Figure S6. Comparison of LC3 II/I ratios in POS-fed BD hiPSC-RPE 
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